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Abstract
Background: Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding
antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and
GABA-A antibodies were found more prevalent in people with psychosis than in healthy controls. We aim to test
whether these antibodies are pathogenic and may cause isolated psychosis. The SINAPPS2 phase IIa double-blinded
randomised controlled trial will test the efficacy and safety of immunoglobulin and rituximab treatment versus
placebo for patients with acute psychosis symptoms as added to psychiatric standard of care.
Methods: We will screen approximately 2500 adult patients with acute psychosis to identify 160 with antibody-positive
psychosis without co-existing neurological disease and recruit about 80 eligible participants to the trial in the period from
September 2017 to September 2021 across the UK. Eligible patients will be randomised 1:1 either to intravenous
immunoglobulin (IVIG) followed by rituximab or to placebo infusions of 1% albumin followed by 0.9% sodium chloride,
respectively. To detect a time-to-symptomatic-recovery hazard ratio of 0.322 with a power of 80%, 56 participants are
needed to complete the trial, allowing for up to 12 participants to drop out of each group.
Eligible patients will be randomised and assessed at baseline within 4 weeks of their eligibility confirmation. The
treatment will start with IVIG or 1% albumin placebo infusions over 2–4 consecutive days no later than 7 days from
baseline. It will continue 4–5 weeks later with a rituximab or sodium chloride placebo infusion and will end 2–3 weeks
after this with another rituximab or placebo infusion. The primary outcome is the time to symptomatic recovery defined
as symptomatic remission sustained for at least 6 months on the following Positive and Negative Syndrome Scale items:
P1, P2, P3, N1, N4, N6, G5 and G9. Participants will be followed for 12 months from the first day of treatment or, where
sustained remission begins after the first 6 months, for an additional minimum of 6 months to assess later response.
Discussion: The SINAPPS2 trial aims to test whether immunotherapy is efficacious and safe in psychosis associated with
anti-neuronal membrane antibodies.
Trial registration: ISRCTN, 11177045. Registered on 2 May 2017.
EudraCT, 2016-000118-31. Registered on 22 November 2016. ClinicalTrials.gov, NCT03194815. Registered on 21 June 2017.
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Background
It is broadly accepted that psychosis and schizophrenia
are caused by genetic and environmental factors, associ-
ated with excess mesolimbic and mesocortical dopamine
and the N-methyl-D-aspartate receptor (NMDAR) hypo-
function [1]. However, a range of cell surface protein
and immune genetic loci are associated with schizophre-
nia [1, 2] and there is increasing evidence for a role of
inflammation in psychosis and schizophrenia [3, 4].
Antibodies binding to neuronal or glial membrane tar-
gets, especially NMDA receptors, in the brain were first
described in 2007 causing encephalopathy, with psychi-
atric features in over two thirds that responded to immuno-
therapy [5]. In such patients, isolated psychotic episodes
occur in 23/571 (4%), either at presentation (5/571) or at
relapse (18/571) [6].
Open-label experience from several hundred patients
suggests that immunotherapy is effective in the full-
blown syndrome of encephalopathy associated with
anti-NMDAR antibodies [7]. Antibodies to the NMDAR
or the voltage-gated potassium channel complex
(VGKC) were found in 3 (7%) out of 46 patients with
first-episode psychosis, without other signs of encephal-
itis [8]. In a prevalence study (PPiP1) we replicated pre-
vious findings as 20 (8.8%) of 228 study participants
with first-episode psychosis possessed these antibodies,
with a rate of 4% in healthy controls [9]. The presence
of NMDAR, of leucine-rich, glioma inactivated 1 (LGI1)
and of gamma-aminobutyric acid type A (GABA-A) re-
ceptor antibodies in patients with a first episode of
psychosis was found to be greater then in healthy con-
trols. We found no cases of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor antibodies
(AMPAR), a greater rate of contactin-associated protein
2 (CASPR2) antibodies in controls than patients with
psychosis, and no difference in VGKC antibodies be-
tween groups [9]. The VGKC antibody radioimmuno-
assay is no longer recommended clinically due to
non-specificity [10]. Others have found NMDAR and
LGI1 antibodies in cases and controls at a low rate [11].
The antibodies were, however, found in neurological and
healthy controls (e.g. 13 of 56 NMDAR antibody-positive
patients in a Cambridge and University College London
(UCL) study had antibodies thought to be clinically ir-
relevant) [12].
There is considerable evidence that anti-NMDAR anti-
bodies are usually pathogenic, down-regulating NMDAR
currents both in vitro and in vivo [13–15]. The hypoth-
esis underlying the SINAPPS2 trial is that these anti-
bodies are pathogenic and may be responsible for
isolated psychosis.
We have recently reported on 18 patients with NMDAR
antibodies, nine of whom self-resolved or responded to
antipsychotics. The remaining nine patients were resistant
to up to three antipsychotics, so we treated them with cor-
ticosteroids combined with either plasma exchange
(PLEX) or intravenous immunoglobulin (IVIG) to good
effect, resulting in reduced serum antibody level, symp-
tomatic remission and lowered disability in the majority of
patients treated, with maintenance therapy for a few pa-
tients (mycophenolate or rituximab) [16].
We conducted an uncontrolled feasibility study
(SINAPPS1) to test the referral pathway and acceptability
of IVIG and PLEX with corticosteroids [17]. Nine (90%)
out of 10 recruited participants with acute psychosis and
the presence of anti-neuronal membrane antibody (antibo-
dy-associated psychosis) received immunotherapy within
14 days from the decision to treat at two acute hospitals in
England. Four participants received IVIG and six were
given plasmapheresis (combined with steroids in four pa-
tients). All participants were taking antipsychotic medica-
tion as prescribed by their psychiatrists. No adverse events
were reported during the treatment. The severity of psych-
osis symptoms and the functioning of all participants im-
proved within two months of the last treatment session.
Symptomatic improvement was remarkable in participants
with NMDAR antibodies and moderate in participants with
VGKC or GABA-A antibodies. The SINAPPS1 trial has
confirmed the feasibility of rapid and safe provision of im-
munotherapy in patients with psychosis in acute hospital
settings. These findings informed the design of the phase
IIa double-blinded randomised clinical trial SINAPPS2.
The SINAPPS2 trial is investigating IVIG and rituximab
versus placebo treatment without corticosteroids.
The SINAPPS2 trial tests the hypothesis that immuno-
therapy is an effective treatment for antibody-associated
psychosis, either the first episode of psychosis or relapse
following previous remission. The trial aims to show su-
periority of immunotherapy with IVIG and rituximab
over conventional psychiatric care alone including anti-
psychotic therapy in patients with acute psychosis and
central nervous system (CNS) membrane antibodies.
The trial was registered at ClinicalTrials.gov on 21
June 2017 (NCT03194815; https://clinicaltrials.gov/ct2/
show/NCT03194815?term=NCT03194815&rank=1).
Trial objectives
The primary objective is to test the efficacy of immuno-
therapy (IVIG and rituximab) in patients with acute
psychosis associated with anti-neuronal membrane anti-
bodies. The secondary objective is to test the safety of
immunotherapy (IVIG and rituximab) in these patients.
Methods
Design
The SINAPPS2 trial is a phase IIa, double-blinded,
multicentre randomised placebo controlled trial with 12
(up to 18 if required) months of follow-up. It will be
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conducted in five to eight acute National Health Service
(NHS) hospital trusts across the UK with suitable facil-
ities for treatment of this population.
Participants
Inclusion criteria
1. Age 18–70 years.
2. Acute psychosis symptoms for at least 2 weeks but
not longer than 24 months in the current episode.
Acute psychosis is defined as rating 4 or more for
at least one of the following Positive and Negative
Syndrome Scale (PANSS) [18] items: P1, delusions;
P2, conceptual disorganisation; P3, hallucinatory
behaviour; N1, blunted affect; N4, social
withdrawal; N6, lack of spontaneity; G5,
mannerisms/posturing; and G9, unusual thought
content. This may be either a first episode or
relapse after remission. Remission is defined as
having mild or absent symptoms of psychosis for at
least 6 months.
3. Serum or cerebrospinal fluid (CSF) anti-neuronal
membrane antibodies at pathological levels (includ-
ing NMDAR, LGI1 and others, as determined by
the Trial Steering Committee).
4. Given informed consent by a patient or their legal
representative.
Exclusion criteria
1. Duration of current episode of psychosis greater
than 24 months.
2. Co-existing severe neurological disease, including
tumour, hippocampal sclerosis with refractory
epilepsy, probable dementia with evidence of
atrophy on brain imaging, moderate or severe
learning disability, or any evidence of a current
acute encephalopathy (for instance coma, seizures).
3. Hepatitis B.
4. Hepatitis C.
5. Human immunodeficiency virus.
6. IgG level < 3 g/L.
7. Previous malignancy (unless agreed with Chief
Investigator (CI)).
8. Pregnant, breast feeding or inadequate
contraception if female.
9. Hypersensitivity or absolute contra-indication to
any trial drug, murine proteins or excipients.
10. Live vaccine within last 3 months.
11. Previous treatment with rituximab in the past 12
months.
12. Severe infection.
13. Severe heart failure.
14. Any other medical illness or disability that, in the
opinion of the investigator, would compromise
effective trial participation.
15. Concurrent enrolment in another Clinical Trial of
Investigational Medicinal Products (CTIMP).
Treatment medication
The interventional treatments are intravenous immuno-
globulin (IVIG) followed one month later by rituximab,
given as two infusions a fortnight apart.
Placebo
Patients receiving control treatment will receive matched
placebo solutions for IVIG (human albumin solution
1%) and rituximab (NaCl 0.9%), with NaCl 0.9% being
used in place of methylprednisolone pre-medication to
maintain blinding.
Route of administration and maximum dosage allowed
The overall duration of the treatment period for an indi-
vidual participant will be approximately 50 days. The
study medication will be used at standard clinical doses,
and delivered as per local protocols. IVIG intravenous
infusion of 2 g/kg (ideal body weight) will be given over
2–4 days as tolerated. Most participants are expected to
receive the drug over two 2–6 h periods. Placebo (1% al-
bumin solution) will be given over 2–4 days.
The IVIG dosage is weight determined (ideal body
weight). Patients below 152.4 cm (5 ft) in height will be
treated using their actual body weigh. IVIG dosing will
be rounded down to the nearest 5 g regardless of the cal-
culated dose; that is, if the calculated dose is 39.9 g, they
will receive 35 g.
The two infusions of 1 g rituximab will be given 14
days apart, over 2–4 h as tolerated, with 100 mg
methylprednisolone pre-medication to reduce infusion-
associated adverse effects. The first infusion will com-
mence at 50 mg/h; after the first 30 min, it may be
escalated in 50mg/h increments every 30min, to a max-
imum of 400 mg/h. In the absence of serious previous
infusion-related reactions, the second infusion can be in-
fused at an initial rate of 100mg/h and increased by 100
mg/h increments at 30-min intervals, to a maximum of
400 mg/h. The matching placebo solution (sodium
chloride 0.9%) will be given in an equal volume and dur-
ation to that used for rituximab infusion. No dosage
modifications are permitted.
The IVIG and matched placebo are provided by Biot-
est Ltd. Rituximab (or bio-similar), matching placebo
and pre-medication will be supplied by local site phar-
macies. Details on identity, supply, packaging, labelling,
label design, prescriptions, dispensing and distribution
of investigational medicinal products are described in
the trial pharmacy manual.
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Concomitant therapy
All prescribed concomitant medications will be recorded
monthly from screening to the end of study visit. Partici-
pants will continue with antipsychotic medications as
standard of care, under the supervision of their local
psychiatrist. Participants will not receive any other inves-
tigational medicinal products during the study period.
Randomisation
An Internet-based system provided by Sealed Envelope
will be used to randomise participants and allocate treat-
ment to individual patients [19]. Eligible patients will be
randomly assigned 1:1 to either the IVIG/rituximab
group or the placebo group before the baseline assess-
ment. Each group will contain approximately 40 partici-
pants. The randomisation will be performed using the
minimisation technique of Pocock and Simon [20],
using NMDAR (yes vs no), LGI1 (yes vs no), GABA-A
(yes vs no), duration of psychotic illness (less than 12
weeks vs 12 weeks and longer) and current smoking
status (currently smoking vs currently not smoking) as
dichotomous minimisation factors.
Notification of treatment allocation will be forwarded
to the central trial coordinator, local investigator and
local pharmacy by email upon randomisation.
Method of blinding
Trial participants and investigators will be blinded to
treatment allocation. Site pharmacies and other authorised
delegates as required will be unblinded. Treatment
products/pre-medication and the corresponding control
will have identical presentations in product appearance,
packaging and labelling.
Primary outcome
The primary outcome is the time to start of symptom-
atic recovery. Symptomatic recovery is defined as symp-
tomatic remission sustained for at least 6 months [21].
Symptomatic remission is defined as a score of 3 or less
on each of the following PANSS [18] items: P1, P2, P3,
N1, N4, N6, G5 and G9.
Secondary outcomes
1. Time to symptomatic remission
Symptomatic remission is defined as a score of 3 or
less on each of the PANSS items P1, P2, P3, N1, N4, N6,
G5 and G9, regardless of whether or not this response is
sustained for 6 months (i.e. response, but does not reach
the duration criterion for recovery).
2. Relapse
Relapse outcome is defined as the proportion of par-
ticipants who relapse at least once during the 12-month
follow-up period. Relapse is defined as a score of 4 or
more on at least one of the PANSS items P1, P2, P3, N1,
N4, N6, G5 or G9 after initial symptomatic remission
occurred during the 12-month follow-up period.
3. Number of adverse events (AEs) over the 12-month
follow-up period
The total number of AEs, total number of serious ad-
verse events (SAEs) and total number of AEs with grade
III or IV as reported in the AE CRF over the 12-month
follow-up period will be presented by randomised group.
4. Number of serious infections
The total number of reported serious infections and
the number of serious infections per participant over the
12-month follow-up period will be reported for each
randomised group.
5. Proportion of patients reaching 20%, 30% and 40%
reduction in PANSS total score over the 12-month
follow-up period.
Trial assessments
Schedule of assessments and visits is summarised in
Fig. 1 according to the SPIRIT statement [22, 23].
Anti-neuronal membrane antibody assays
We use a live cell-based assay system [24] to identify
serum anti-neuronal membrane antibodies. We have
identified criteria to attempt to distinguish clinically ir-
relevant cases of positive anti-NMDAR and VGKC com-
plex antibodies from pathogenic antibodies [12, 25].
Anti-neuronal membrane antibody assays will be per-
formed for NMDAR, LGI1 and GABA-A antibodies.
During the course of the study, other relevant anti-neur-
onal antibodies may be discovered and the protocol al-
lows for these to be included, as determined by the Trial
Steering Committee. Anti-neuronal membrane anti-
bodies will be assessed at screening, the first rituximab
treatment visit (28–35 days), at 6 and 12-month
follow-up, and at the end of study clinical visit.
Safety monitoring
The screening blood tests will be performed only at the
screening visit and will include urea, electrolytes,
calcium, HIV, hepatitis B, hepatitis C, syphilis, pneumo-
coccal and varicella serology.
The monitoring blood samples will be taken at the
screening visit, at 6 and 12-month follow-up visits and
at the end of study clinical visit. Monitoring blood tests
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include FBC, liver function tests (LFT) and immuno-
globulin levels.
Pregnancy is an exclusion factor. A pregnancy test (urine
sample) will be conducted with female participants at the
screening visit to confirm the eligibility of a potential trial
participant. A further pregnancy test will be performed at
the baseline visit (no longer than 7 days before the first dose
of IVIG). Another and final pregnancy test should be taken
no longer than 7 days before the first dose of rituximab.
The trial participants’ or their partners’ pregnancies
during the trial period and up to 2 years after trial enrol-
ment will be reported using the relevant Pregnancy
Reporting Forms within 24 h of notification.
Primary outcome measure
The Positive and Negative Syndrome Scale (PANSS) [18]
is a clinician/researcher-rated 30-item scale for the as-
sessment of the severity of symptoms of schizophrenia
based on information obtained from a patient during the
interview and from their family members and clinicians.
Each item is rated from 1 (absent) to 7 (extreme) and
they are grouped into three subscales: Positive Scale, P
(7 items); Negative Scale, N (7 items); and General
Psychopathology Scale, G (16 items). The sum of indi-
vidual ratings within each subscale gives score ranges of
7–49 for the Positive Scale and Negative Scale and of
16–112 for the General Pathology Scale. A higher score
indicates severe symptoms.
The primary outcome will be assessed by eight se-
lected PANSS items [21]. These include three Positive
Scale items (P1, delusions; P2, conceptual disorganisa-
tion; P3, hallucinatory behaviour), three Negative Scale
items (N1, blunted affect; N4, passive/apathetic social
withdrawal; N6, lack of spontaneity) and two items from
the General Pathology Scale (G5, mannerisms/posturing;
G9, unusual thought content).
PANSS assessments will be conducted by trained re-
searchers. Their training includes PANSS training by
Fig. 1 Trial assessments. 1Only weight at the end of study visit. 2The required screening blood tests are urea, electrolytes, calcium, HIV, hepatitis B,
hepatitis C, syphilis, pneumococcal and varicella serology. 3Full blood count, liver function tests and immunoglobulins. 4Only at month 6, 12 and
end of trial visit. IVIG intravenous immunoglobulin, PANSS Positive and Negative Syndrome Scale
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certified trainers followed by observed role-play inter-
views with feedback, observed mock interviews with
non-patients and patients with psychosis, and mock-
interview videoing and analysis. Thereafter, there will be
periodical refresher training with certified PANSS
trainers and researchers’ independent rating of individ-
ual patient video interviews over the trial period.
Trial procedures
Identification of potential participants and enrolment
Participants will be identified to a SINAPPS2 trial
neurologist either by referral from their mental health
care team after receiving positive results for their rou-
tine antibody testing in clinical practice or after hav-
ing been tested within the screening study on the
prevalence of antibody-associated psychosis (PPiP2
study, REC ref: 12/EE/0307). The trial flow is sum-
marised in Fig. 2.
Antibody-positive patients will be given the patient
information sheet and members of the research team
will clarify any information which may preclude
recruitment. Informed consent will be obtained by a re-
searcher or a doctor at the screening visit before
trial-specific assessments.
Participants lacking the capacity to make a decision to
take part in the study will be approached to be enrolled
in the study under the conditions and principles listed in
the Medicines for Human Use (Clinical Trials) Regula-
tions [26].
A Personal Legal Representative (PeLR) close to that
incapacitated patient, aware of his/her wishes and inde-
pendent of the research, should be approached first to
provide written consent. If it is not possible to approach
a personal legal representative or there is no one suffi-
ciently close to the potential participant who is willing
or able to take on the role, then an independent clinician
will be nominated to act as Professional Legal Represen-
tative (PrLR) to fulfil this role. The PrLR in the
SINAPPS2 trial is defined as a person who is not con-
nected with the conduct of the trial, specifically not the
Sponsor of the trial, nor a person employed or engaged
by acting under the arrangements with the Sponsor, and
who undertakes activities connected with the manage-
ment of the trial, not an investigator of the trial and not
a health care professional who is a member of the inves-
tigators’ team for the purposes of the trial.
Participants who regain capacity will be informed of
the clinical trial and consent to continue will be sought
at that time as per the usual consenting process.
If a participant consents to the trial but later becomes
incapacitated, the original consent given remains valid
after the loss of capacity, providing that the trial has not
significantly altered.
Screening, baseline, treatment and follow-up
Outline
Screening assessments and procedures, summarised in
Fig. 1, will only be conducted after a participant has
signed the consent form. Participants will be randomised
after confirmation of their eligibility, and before the
baseline visit. The eligibility must be confirmed within a
maximum of 2 months from the informed consent.
There is no other time limit for randomisation. The
baseline visit will be scheduled a maximum of 4 weeks
after confirmation of eligibility and a maximum of 7
days before IVIG/placebo treatment. Rituximab first in-
fusion will follow after 4–5 weeks and rituximab second
infusion 2–3 weeks later. All trial participants will be re-
quired to attend follow-up clinical visits at 3, 6, 9 and
12months, which will be an end of study visit. Partici-
pants may need to be followed for longer and attend a
clinical visit at month 15 and 18 if the primary outcome
data need to be obtained beyond month 12. In addition,
a monthly follow-up brief telephone or visit assessment
will be administered by researchers. Anonymised data
will be transferred in Case Report Forms (CRFs) by the
trial researchers and clinicians. All CRFs will be com-
pleted in the manner, and within the timelines, detailed
in the CRF-completion guidelines and sent to the trial
coordinator at the Cambridge Clinical Trials Unit
(CCTU). The CRFs will be accessible to trial coordina-
tors, data managers, the investigators, clinical trial moni-
tors, auditors and inspectors as required. All trial data
will be entered and stored in a MACRO database. A
trial-specific data management plan will describe in de-
tail the data management processes.
1. Screening visit and Assessments (Visit 1)
The screening visit and assessments will usually be
performed at the SINAPPS2 site local clinical research
facility, but may also be performed at outpatient clinics.
Informed signed consent will be obtained and this will
be followed by screening assessments to establish eligi-
bility. These will include physician review, physical
examination, height and weight assessments, pregnancy
test (urine sample) if appropriate, collection of demo-
graphic data and disease history, screening blood tests,
monitoring blood tests, anti-neuronal membrane anti-
body assays, blood sample for future research, assess-
ment of PANSS items P1, P2, P3, N1, N4, N6, G5 and
G9, and concomitant medications.
2. Baseline visit and assessments (Visit 2 (day 0,
maximum 7 days before IVIG/placebo treatment))
The baseline visit will follow confirmation of a partici-
pant’s eligibility and randomisation. It will be arranged a
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maximum of 4 weeks after confirmation of eligibility.
Participants will be reviewed by a physician for the
period between screening and baseline dates. Clinical as-
sessment (PANSS), assessment of adverse events and
concomitant medication will be administered by a
researcher.
3. IVIG or placebo treatment (Visit 3 (days 1–4))
The first treatment will follow the baseline visit (0–7
days after baseline) and will be given in an appropriate
outpatient or inpatient setting, as determined by local
practice and clinical need. Data on adverse events and
concomitant medication will be obtained.
4. Rituximab or placebo 1 treatment (Visit 4 (day 28,
+ 7 days)
Rituximab or placebo first treatment will be given in
an appropriate setting, as determined by local practice
and clinical need. Anti-neuronal membrane antibody as-
says and a pregnancy test (a maximum of 7 days before
Fig. 2 Trial flow chart. IVIG intravenous immunoglobulin
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the first dose of rituximab/placebo) will be taken and
data on adverse events and concomitant medications
will be recorded.
5. Rituximab or placebo 2 treatment (Visit 5 (day 42,
+ 7 days)
Rituximab or placebo second treatment will take place
14 (+ 7) days after the rituximab first treatment and data
on adverse events and concomitant medications will be
collected.
6. Follow-up clinical visits (months 3, 6 and 9 (12 and
15), ± 7 days)
Each study participant will be followed for 12
months from the day of first treatment (IVIG/pla-
cebo). There will be an additional maximum 6
months of follow-up, if required, to assess the
primary outcome if the participant enters clinical
remission between months 7 and 12 (to include
follow-up for a further 6 months from the point of
entering clinical remission). Participants will be
assessed every 3 months (at months 3, 6 and 9 (and
months 12 and 15 if required for participants
requiring longer follow-up) ± 7 days). At follow-up
clinical visits there will be a physician review, a
physical examination, assessment of severity of
symptoms (PANSS), adverse events and concomitant
medications. In addition, monitoring blood tests and
anti-neuronal membrane antibody assays will be
performed at month 6 (and month 12).
7. End of trial visit (month 12 (or 15 or 18) ± 7 days).
Participation will end 12months after the first day of
treatment, or at 15 or 18 months if required. Assess-
ments will include a physician review, physical examin-
ation, weight, monitoring blood tests, anti-neuronal
membrane antibody assays, assessment of PANSS, ad-
verse events and concomitant medications.
Participants will return to a normal standard of care
after participation in the trial, which is likely to be a
local psychiatry review, with a neurologist’s input and re-
view if antibodies and symptoms return.
8. Monthly telephone or visit follow-up assessments
will be conducted by researchers to assess the
primary outcome, adverse events and concomi-
tant medication at months 1, 2, 4, 5, 7, 8, 10 and
11 (months 13, 14, 16 and 17 if required) ± 3
days. A month-one follow-up assessment will be
conducted at the first rituximab treatment visit
on day 28 (+ 7).
Emergency unblinding
In the event of a clinical adverse event, where knowledge
of the treatment allocation will alter management, the
treating physician may unblind the patient using the
web-based randomisation system (through a procedure
documented in the trial manual/randomisation system
manual). It is the responsibility of the treating physician
to promptly document and explain any unblinding to
the Sponsor.
Withdrawal
Patients who have withdrawn from the allocated treat-
ment will remain in the trial and be followed up as set
out in the protocol, unless they withdraw their consent
for this trial. Any data and samples collected up until that
point of consent withdrawal will continue to be used in
the trial. However, no further information will be collected
or tests performed. Participants who withdraw between
randomisation and treatment will be replaced.
In addition, participants must be withdrawn from their
allocated treatment arm if they develop severe encephal-
opathy (e.g. typical of NMDAR encephalitis or
LGI1-antibody encephalopathy), which would necessitate
withdrawal to facilitate best standard of care of manage-
ment for these conditions [7]; the participant develops
severe reactions to the Investigational Medicinal Prod-
ucts (IMP) (e.g. anaphylaxis to first rituximab infusion,
aseptic meningitis to first dose of IVIG); or a female
participant becomes pregnant or will no longer use
contraception.
Trial restrictions
Women of childbearing potential are required to use ad-
equate contraception for the duration of the trial and for
12 months after the last treatment. Men are required to
use adequate contraception for the entire duration of
the trial and for 90 days after the completion of the last
treatment. Male participants should refrain from
donating sperm for the duration of the trial and for 12
months thereafter.
Sample size
To estimate the control rate for the primary outcome ef-
ficacy measure, we have re-analysed the raw data of the
National EDEN study [27]. This study consisted of 1000
patients with psychosis (antibody associations not
known); 19% of those, who were symptomatic at entry,
experienced sustained remission as per the Andreasen et
al. criteria [21] on standard antipsychotic therapy at 1
year. The 50% remission rate on immunotherapy that we
have selected is a conservative estimate; in anti-NMDAR
encephalopathy, remission may be as high as 85% at 1
year following IVIG and rituximab [7]. We agreed on
50% as a clinically meaningful and important remission
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rate that from a patient perspective would make partici-
pation in the trial acceptable. The Trial Steering Com-
mittee (TSC) and statistician will analyse recruitment
and dropout rates at months 12 and 24 of the trial, and
consider altering the recruitment strategy. We have
chosen a sample size to target a time-to-remission haz-
ard ratio of 0.322 with a one-sided type I error rate of
5% and a power of 80%, standard for a stage II clinical
trial. This target hazard ratio comes from assuming a
1-year remission probability of 0.2 in the control arm
and 0.5 in the experimental arm and assuming the
time-to-remission distribution is exponential with pro-
portional hazards. With all participants followed up for
1 year, a sample size of 56 participants equally rando-
mised between the control and experimental arms is re-
quired. The sample size was calculated using NCSS
PASS v14. We intend to recruit about 80 participants,
allowing dropout of 12 participants per arm. This level
of dropout is a cautious estimate because, although a
high dropout is often seen in drug trials in psychosis, we
are not requiring continued compliance with medication
regimes after the infusions of IVIG and rituximab.
Statistical analysis methods
The final analysis will use a Cox proportional hazards
model with fixed effects for minimisation covariates.
The primary analysis will be per protocol rather than
intention to treat, although both will be done. Secondary
and exploratory outcomes will be analysed with Cox
models (time to any remission), logistic regression
models (relapse rate, proportion of participants with ser-
ious adverse events) and Poisson models (number of
adverse events). The per-protocol population is defined
as all participants who have received all protocol-
defined IMPs, and have no major protocol violation
as defined prior to analysis. A full detailed analysis
plan will be prepared by a statistician who is inde-
pendent from the study.
Data on trial progress such as recruitment and partici-
pant dropout at months 12, 24 and 36 of the trial (after
activation of the first site) and quality of data will be re-
ported to both the Trial Steering Committee and the
Data Monitoring Committee (DMC). The Trial Steering
Committee will consider opening additional sites and/or
modifying eligibility criteria if recruitment rates are
below those expected. There will be no interim analyses
of efficacy.
Trial management
The ethical and safety aspects of the trial (e.g. rate of
severe adverse events/severe adverse reactions) will be
reviewed by the Data Monitoring Committee.
The DMC will meet (virtually if necessary) at least an-
nually to consider the safety data emerging from the
trial. The committee may request unblinded data and
more frequent listings if necessary. The DMC reports to
the CI and the Trial Steering Committee.
The TSC will provide overall supervision with respect to
the conduct of the trial. Full details of the TSC and DMC
membership and remit can be found in the TSC and
DMC Charters. Both are available from the CI on request.
The Trial Management Group (TMG) (CI, Principal
Investigators (PIs), trial statistician, trial coordinator,
psychiatrists and project manager) meets weekly,
manages the trial overall and discusses key decisions.
Data protection and patient confidentiality
All investigators and trial site staff involved in this trial
will comply with the requirements of the Data Protec-
tion Act 1998 and Trust Policy with regards to the col-
lection, storage, processing and disclosure of personal
information and will uphold the Act’s core principles.
Only anonymised data will be received by the trial co-
ordination team. Patient personal data will be kept
locally at each site in secure locked cabinets or electron-
ically on encrypted secure drives.
Sponsor
The trial Sponsor is Cambridge University Hospitals
NHS Foundation Trust & the University of Cambridge
(Mrs Carrie Bayliss, Cambridge Clinical Trials Unit,
Coton House Level 6, Box 401, Addenbrooke’s
Hospital, Hills Road, Cambridge CB2 0QQ, UK; cctu@-
addenbrookes.nhs.uk). The trial Sponsor did not have a
role in the study design, collection, management, writ-
ing of the paper and decision to submit the paper for
publication, and it has no ultimate authority over any
of these activities.
Insurance
Cambridge University Hospitals NHS Foundation Trust,
as a member of the NHS Clinical Negligence Scheme for
Trusts, will accept full financial liability for harm caused
to participants in the clinical trial through the negligence
of its employees and honorary contract holders. There
are no specific arrangements for compensation should a
participant be harmed through participation in the trial
if no-one has acted negligently.
The University of Cambridge will arrange insurance
for negligent harm caused as a result of protocol design
and for non-negligent harm arising through participation
in the clinical trial.
Monitoring, audit and inspection
All trial documentation and related records will be available
should a Medicines and Healthcare products Regulatory
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Agency (MHRA) Inspection or a monitoring visit or audit
of the Sponsor’s representative occur. The Sponsor’s moni-
toring frequency will be determined by an initial risk assess-
ment performed prior to the start of the trial. A detailed
monitoring plan will be generated detailing the frequency
and scope of the monitoring for the trial. Throughout the
course of the trial, the risk assessment will be reviewed and
the monitoring frequency adjusted as necessary. Remote
monitoring will be conducted for all participating sites. The
scope and frequency of the monitoring will be determined
by the risk assessment and detailed in the Monitoring Plan
for the trial.
Publications policy
Ownership of the data arising from this trial resides with
the trial team. On completion of the trial, the data will
be analysed and tabulated and a Final Trial Report pre-
pared. The funders of the trial will be acknowledged.
Participants will be informed of the outcome of the trial
through the trial website. The trial findings will be re-
ported in peer-reviewed journals.
Discussion
The SINAPPS2 trial has significant potential implica-
tion for the understanding and management of psych-
osis. Consequently, it could have a profound impact on
the improved health of a group of patients presenting
with psychosis.
Anti-inflammatory treatments have been shown to have
some beneficial effects in schizophrenia. Although im-
munotherapy is already used to treat psychosis patients
with neurological disease, this is the first randomised con-
trolled trial designed to test immunotherapy for patients
with anti-neuronal membrane antibodies and acute psych-
osis without co-occurring severe neurological disease. The
SINAPPS2 trial will contribute to a limited but growing
body of evidence about the role of pathogenic anti-neur-
onal membrane antibodies in psychosis.
The data from open non-randomised studies [16, 17]
using IVIG and PLEX for patients with acute psychosis
and presence of anti-neuronal membrane antibodies are
promising. Findings suggest that IVIG and PLEX have a
positive safety profile, and IVIG but not PLEX is accept-
able to participants. Psychosis symptoms of participants
in both studies were improved. The SINAPPS2 trial will
investigate patients’ views on acceptability and safety of
combined IVIG with rituximab. The clinical pathway for
these patients is still not clear and may be a challenge
during the trial, but the SINAPPS2 trial has the potential
to explore and introduce an efficient clinical pathway for
assessment and treatment of patients with antibody-as-
sociated psychosis in neurology clinics.
Limitations
The study will provide evidence on the efficacy of treat-
ment but its effectiveness would still have to be tested in
a future phase of the trial. All participants will continue
with their antipsychotic medication treatment during the
trial. This may mask the detection of the actual effect of
immunotherapy or distinguishing effects of each treat-
ment (antipsychotics and immunotherapy). The design
of the trial, specifically the method of the IMP adminis-
tration, has introduced potential selection bias. The trial
participants are required to endure intravenous treat-
ments over several hours per day. This may be difficult
for patients with extremely severe psychosis symptoms
and they may not be initially included in the trial.
However, they may be re-approached when the severity
of their symptoms no longer prevents them undertaking
lengthy intravenous treatment.
Trial status
Valid trial protocol at time of submission: v3; 20/12/2018.
Participants are currently being recruited and enrolled.
The recruitment began on 25 September 2017 and the
first participant was enrolled on 27 September 2017. At
the time of submission there were seven enrolled partici-
pants. The estimated end date of the recruitment is 31
December 2020 and the trial completion date is 31
December 2021. The populated SPIRIT [22, 23] checklist
is provided as Additional file 1.
Contact: www.sinapps.org.uk; sinapps@psych.ox.ac.uk;
@SINAPPS_group; @SINAPPSgroup.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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